<DOC>
	<DOCNO>NCT02609334</DOCNO>
	<brief_summary>This double-blind , randomise , placebo-controlled , cross-over , Phase 2 trial evaluate two dos ( low high ) CRD007 treatment asthmatic trial subject positive asthma test ( mannitol challenge ) prior enrolment .</brief_summary>
	<brief_title>RSPR-007 Mannitol Challenge Trial</brief_title>
	<detailed_description>The present trial include subject diagnose asthma provocation model mimic assessment asthma control . Mannitol challenge indirect asthma provocation test , require presence inflammatory cell , particularly mast cell , airway . The trial involve total 5 subject visit last maximum 30 day subject Visit 2 ( Randomisation ) Visit 5 ( Follow ) . Visit 2,3 , 4 treatment visit Investigational Medicinal Product ( IMP ) administrate 3 hour Mannitol challenge .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Pemirolast</mesh_term>
	<criteria>Written inform consent Age â‰¥18 &lt; 50 year Diagnosis asthma Clinical significant comorbidities Lower respiratory tract infection &lt; 6 week prior Visit 1 Others , specify protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>